Palisade Bio
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1902 Wright Pl Ste 200, Carlsbad, Califo...Phone Number
(858) 704-4900Website
www.palisadebio.comRevenue
-Stock Symbol
PALIIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Palisade Bio
Palisade Bio is a late-stage biopharma company advancing therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Lead asset LB1148 is a Phase 3-ready protease inhibitor with potential to both reduce abdominal adhesions and help restore bowel function following surgery. Positive data from Phase 2 trials of LB1148 demonstrated safety and tolerability as well as a statistically significant improvement in return to bowel function and decrease in length of stay in ICU and hospital compared to placebo.Explore more
Palisade Bio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Palisade Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Palisade Bio
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Palisade Bio launches new products
Click to see if Palisade Bio had a recent Job posting/layoffs
Earning: See what the market has to say on Palisade Bio recently announced quarterly report
Funding: Get notified immidiatlly once Palisade Bio has new funding data
Palisade Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Palisade Bio has recently received funding, and reach out quickly before it becomes old news!
Check out if Palisade Bio is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Palisade Bio as Masked Content
Find 3 more new buyers
Compare Similar Companies to Palisade Bio
Compare insights from companies similar to Palisade Bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Palisade Bio is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Palisade Bio is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Palisade Bio.
Palisade Bio financials insights
Gather financial insights about Palisade Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Stock/Share Issuance
$3.9M
2026
Private Equity
$500K
Palisade Bio Tech Stack
A closer look at the technologies used by Palisade Bio
See more technologies
Most Recent Scoops
Project
Palisade Bio has reported that its PALI-2108 is an oral, novel, locally-targeted drug with a dual mechanism of action (anti-inflammatory and anti-fibrotic) designed to improve tolerability compared to existing oral therapies in the IBD space.
Product Development, Pharmaceuticals
Project
Palisade Bio has reported that its Phase 1B study of PALI-2108 in ulcerative colitis showed a 63% improvement in modified Mayo score, 100% response rate, and 40% clinical remission rate after just one week of treatment, including a five-day titration period.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Palisade Bio has reported that its Phase 1B study showed that PALI-2108 maintained therapeutic drug levels well above the IC90 at steady state trough and even 36 hours after dosing.
Medical Research, Pharmaceuticals
Project
Palisade Bio is planning a definitive ulcerative colitis study to begin mid-year, with 65 patients per arm (high dose, low dose, and placebo), a 12-week induction period, blinded maintenance through 52 weeks, and a primary endpoint of clinical remission at 12 weeks.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Medical Research, Pharmaceuticals
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Palisade Bio
Sign Up For FreeTo access detailed company insights
Palisade Bio is a late-stage biopharma company advancing therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Lead asset LB1148 is a Phase 3-ready protease inhibitor with potential to both reduce abdominal adhesions and help restore bowel function following surgery.... Read More
